New strategies for the treatment of ovarian cancer.
Ovarian cancer usually responds well to chemotherapy, but once the disease becomes resistant to chemotherapy, the treatment options available are inadequate. A number of strategies are currently undergoing clinical evaluation, among which angiogenesis and PARP [poly(ADP-ribose) polymerase] inhibitors appear promising. Pre-clinical studies have identified several potential new therapeutic strategies, and we review the potential for use of BH3 (Bcl-2 homology) mimetics, autotaxin inhibitors and statins to treat ovarian cancer.
*Institute for Science and Technology in Medicine and School of Pharmacy, Guy Hilton Research Centre, Keele University, Thornburrow Drive, Stoke-on-Trent, Staffordshire ST4 7QB, U.K.
Elizabeth
E
Robinson
*Institute for Science and Technology in Medicine and School of Pharmacy, Guy Hilton Research Centre, Keele University, Thornburrow Drive, Stoke-on-Trent, Staffordshire ST4 7QB, U.K.
Natalie
N
Fisher
Vasileios
V
Stamelos
†University Hospital of North Staffordshire, Newcastle Road, Stoke-on-Trent, Staffordshire ST4 6QG, U.K.
Charles
C
Redman
*Institute for Science and Technology in Medicine and School of Pharmacy, Guy Hilton Research Centre, Keele University, Thornburrow Drive, Stoke-on-Trent, Staffordshire ST4 7QB, U.K.
Alan
A
Richardson
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D018716:Molecular Mimicry; D058990:Molecular Targeted Therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010726:Phosphodiesterase Inhibitors; D019253:Proto-Oncogene Proteins c-bcl-2